Rekombinanter CPA1 Antikörper (full length)

Produktnummer ABIN7877792

Dieser Kaninchen Monoklonal Antikörper detektiert spezifisch CPA1 in IHC (p). Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für Rekombinanter CPA1 Antikörper (full length) (ABIN7877792)

Target: CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser CPA1 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: CPA1-8258R

Produktdetails anti-CPA1 Antikörper

Bindungsspezifität: full length

Verwendungszweck: Carboxypeptidase A1 Antibody / CPA1 (azide and preservative free)

Aufreinigung: Protein A/G affinity

Immunogen: Recombinant full-length human protein was used as the immunogen for the Carboxypeptidase A1 antibody.

Isotyp: IgG, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the Carboxypeptidase A1 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the Carboxypeptidase A1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu CPA1

Target: CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))

Andere Bezeichnung: Carboxypeptidase A1

Hintergrund: Human pancreatic procarboxypeptidase A exists as three different active forms, two of which are designated carboxypeptidase A1 (CPA1) and carboxypeptidase A2 (CPA2). CPA1, also known as CPA, is a 419 amino acid secreted monomeric protein that is highly expressed in pancreatic tissue. Functioning as a pancreatic exopeptidase, CPA1 uses zinc as a cofactor to catalyze the release of C-terminal amino acids from a variety of proteins, thereby playing a key role in protein digestion and degradation. Via its catalytic activity, CPA1 is also thought to be involved in zymogen (proenzyme) inhibition, probably functioning to block enzyme activation pathways. Abnormal levels of CPA1 are associated with pancreatic cancer, suggesting a possible role in either tumor progression or tumor suppression events.

UniProt: P15085